211 related articles for article (PubMed ID: 9500194)
1. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.
Di Loreto C; Puglisi F; Di Lauro V; Damante G; Beltrami CA
Cancer Lett; 1998 Feb; 124(1):73-8. PubMed ID: 9500194
[TBL] [Abstract][Full Text] [Related]
2. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
Bakir K; Koçer NE; Deniz H; Güldür ME
Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737
[TBL] [Abstract][Full Text] [Related]
3. Expression of thyroid transcription factor-1 in malignant pleural effusions.
Khoor A; Byrd-Gloster AL; Nicosia SV
Pathol Oncol Res; 2011 Jun; 17(2):263-7. PubMed ID: 20848248
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
5. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
7. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
8. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma.
Khoor A; Whitsett JA; Stahlman MT; Olson SJ; Cagle PT
Hum Pathol; 1999 Jun; 30(6):695-700. PubMed ID: 10374779
[TBL] [Abstract][Full Text] [Related]
9. [Surfactant protein and thyroid transcription factor 1 in pleuro-pulmonary neoplasia. Immunohistochemical study].
Dessy E; Falleni M; Del Curto B; Braidotti P; Pietra GG
Pathologica; 2000 Dec; 92(6):496-502. PubMed ID: 11234300
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
Afify AM; al-Khafaji BM
Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029
[TBL] [Abstract][Full Text] [Related]
11. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409
[TBL] [Abstract][Full Text] [Related]
12. Expression of snail, twist, and Zeb1 in malignant mesothelioma.
Merikallio H; Pääkkö P; Salmenkivi K; Kinnula V; Harju T; Soini Y
APMIS; 2013 Jan; 121(1):1-10. PubMed ID: 23030626
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
14. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
15. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
Ordóñez NG
Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
[TBL] [Abstract][Full Text] [Related]
16. N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas: a ThinPrep immunocytochemical study.
Han AC; Filstein MR; Hunt JV; Soler AP; Knudsen KA; Salazar H
Cancer; 1999 Apr; 87(2):83-6. PubMed ID: 10227598
[TBL] [Abstract][Full Text] [Related]
17. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
18. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P
Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651
[TBL] [Abstract][Full Text] [Related]
19. Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
Lindholm PM; Soini Y; Myllärniemi M; Knuutila S; Heikinheimo M; Kinnula VL; Salmenkivi K
J Clin Pathol; 2009 Apr; 62(4):339-44. PubMed ID: 19060016
[TBL] [Abstract][Full Text] [Related]
20. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
